BrainStorm Announces FDA AdComm Meeting for NurOwn Stromal Cell Therapy

Published Date: 30 Mar 2023

NurOwn, an autologous mesenchymal stromal cell approach to ALS, failed to meet pivotal Phase 3 trial endpoints, but subsequent testing showed promising results for less severe disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

Glioblastoma treatment breakthrough shows promise

3.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

4.

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

5.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot